Biomarcadores comunes y emergentes

La aplicabilidad de los biomarcadores al manejo del cáncer es variable1

Ejemplos de biomarcadores comunes y emergentes5,7–18

limination-phase

KRAS = Homólogo del oncogén viral del sarcoma de la rata Kirsten; RAS = sarcoma de rata; RAF = fibrosarcoma de rápida aceleración; MAPK = cinasas de proteína activadas por mitógeno; BRAF = proto oncogén B-Raf, cinasa de serina/treonina; EGFR = receptor de factor de crecimiento epidérmico; ALK = cinasa de linfoma anaplásico; ERK = cinasa regulada por señal extracelular; MEK=MAPK/Erk kinase; PI3K = fosfatidilinositol 3-cinasa; AKT = oncogén asociado a retrovirus; JAK = janus cinasa; STAT = transductor de señal y activador de transcripción;9T HER2 = receptor de factor de crecimiento epidérmico humano 2; PD-L1=ligando 1 del receptor de muerte celular programada 1 Ligando 1 del receptor de muerte celular programada 1, una proteína de la transmembrana que se une a su receptor, PD-1.3,7 ; PD-1 = receptor de muerte celular programada 1; PIK3CA = fosfatidilinositol-4,5-bifosfato 3-cinasa, subunidad catalítica alfa; c-MET = factor de transición celular–mesenquimal a epitelial; NRAS = homólogo del oncogén viral RAS (v-ras) del neuroblastoma.

 

Conozca más acerca de los biomarcadores en la actualidad

Referencias: 1. Modur V, Hailman E, Barrett JC. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics. Clin Chem. 2013; 59(1):102–109. 2. Engstrom PF, Bloom MG, Demetri GD, y cols. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw. 2011; 9(suppl 6):S1–S16. 3. Mehta S, Shelling A, Muthukaruppan A, y cols. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2010; 2(2):125–148. 4. National Cancer Institute. NCI dictionary of cancer terms. Disponible en: http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=46259. Consultado el 10 de diciembre de 2015. 5. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015; 14(4):OF1–OF10. 6. National Cancer Institute. National Institutes of Health. Targeted cancer therapies. Disponible en: http://www.cancer.gov/cancertopics/treatment/types/targeted-therapies/targeted-therapies-fact-sheet . Consultado el 10 de diciembre de 2015. 7. Schmoll HJ, Van Cutsem E, Stein A, y cols. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol. 2012; 23(10):2479–2516. 8. Febbo PG, Ladanyi M, Aldape KD, y cols. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011; 9(suppl 5):S1–S32. 9. National Cancer Institute. National Institutes of Health. Tumor markers. Disponible en: http://www.cancer.gov/cancertopics/factsheet/Detection/tumor-markers. Consultado el 10 de diciembre de 2015. 10. Jakob JA, Bassett RL Jr, Ng CS, y cols. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118(16):4014–4023. 11. Reck M, Popat S, Reinmuth N, y cols. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25(suppl 3):iii27–iii39. 12. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006; 12(18):5268–5272. 13. Tabbó F, Barreca A, Piva R, y cols. ALK signaling and target therapy in anaplastic large cell lymphoma. Front Oncol. 2012; 2: 41. doi: /fonc.2012.00041. eCollection 2012. 14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252–264. 15. Hafsi S, Pezzino FM, Candido S, y cols. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol. 2012; 40(3):639–644. 16. Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol. 2014; 20(14):3858–3874. 17. Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011; 3(suppl 1):S7–S19. 18. Gaule PB, Crown J, O' Donovan N, y cols. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? Expert Opin Ther Targets. 2014; 18(9):999–1009.

04-21-ONCO-1129302-0005 Clave SSA: 163300202C5918